Dare Bioscience, Inc. (DARE) Stock Price, Financials & Summary

Price chart

Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29

Key dataOct 29, 2026

Open$0.69

From 52W high−79.16%

Volume46983.00

Market cap$13.40M

P/E (TTM)—

P/S (TTM)9.8x

Div yield—

Key dataOct 29, 2026

Open

$0.69

From 52W high

−79.16%

Volume

46983.00

Market cap

$13.40M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

P/E (TTM)

—

RSI (14)

41.0

MomentumView details →

1D Return

+0.22%

YTD Return

−64.05%

SummaryUpdated Jun 1, 2026

Daré Bioscience, Inc. (NASDAQ:DARE) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California. The company focuses exclusively on developing and commercializing innovative healthcare products for women's health, addressing unmet medical needs across contraception, fertility, sexual health, and vaginal health. Since its IPO in April 2014, Daré has built a diverse pipeline of 12 development-stage candidates targeting nine different women's health indications, with its first FDA-approved product <b>XACIATO</b> launched commercially in 2024 through a partnership with Organon.

Ask drillr about Dare Bioscience, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.9x

EV/Sales

5.5x

P/S (TTM)

9.8x

P/B (TTM)

−23.9x

ProfitabilityView details →

Gross Margin

−89.45%

Net Margin

−804.37%

EBITDA Margin

−630.71%

ROE (TTM)

1961.64%

ROA (TTM)

−49.12%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

+7816.73%

EPS YoY

+63.28%

FCF YoY

+0.96%

Revenue CAGR 3Y

−53.12%

EPS CAGR 3Y

—

EBITDA YoY

+50.94%

MomentumView details →

1D Return

+0.22%

YTD Return

−64.05%

1Y Return

−64.05%

RSI (14)

41.0

vs 50D SMA

−7.74%

vs 200D SMA

−56.28%

Capital & dividendView details →

Debt/Equity

−12.08x

Current Ratio

0.99x

Quick Ratio

0.99x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.20

EPS Surprise

32.59%

Beats (12Q)

11/12

Next Q EPS Est

−$0.23

Avg Surprise (4Q)

44.70%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.37M

Net Income (TTM)

−10.99M

Op. CF (TTM)

−11.29M

Next earningsNov 12, 2026 →

Latest newsMore news →

Daré Bioscience announced premier sponsorship of Dare Bioscience, Inc. and the Dare Bioscience, Inc.’s continuing medical education program on managing menopause after breast cancer.11d ago

Dare Bioscience, Inc. launched a “CEO Corner” video series featuring CEO Sabrina Martucci Johnson to discuss the company’s women’s health portfolio, clinical pipeline and strategic priorities.17d ago

Similar companies

Adial Pharmaceuticals, Inc.ADIL TScan Therapeutics, Inc.TCRX Fractyl Health, Inc. Common StockGUTS Psyence Biomedical Ltd.PBM Synlogic, Inc.SYBX Cuprina Holdings (Cayman) Limited Class A Ordinary SharesCUPR Find similar companies →

Latest newsMore news →

Daré Bioscience announced premier sponsorship of Dare Bioscience, Inc. and the Dare Bioscience, Inc.’s continuing medical education program on managing menopause after breast cancer.11d ago Dare Bioscience, Inc. launched a “CEO Corner” video series featuring CEO Sabrina Martucci Johnson to discuss the company’s women’s health portfolio, clinical pipeline and strategic priorities.17d ago